Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial

Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial

Background: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in patients harboring epidermal growth factor receptor (EGFR) m...

Full description

Bibliographic Details
Main Authors: Ming Gao, Xia Zhang, Huan Yan, Yan Zhao, Fang Yuan, Decong Sun, Xuejiao Yang, Yanfang Ju, Lijie Wang, Haitao Tao, Luyuan Tian, Changhong Zhao, Junxun Ma, Yi Hu, Zhefeng Liu
Format: Article
Language:English
Published: SAGE Publishing 2025-01-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359241311058

Internet

https://doi.org/10.1177/17588359241311058

Similar Items